Home » Newsletters » BioWorld Science

BioWorld Science

June 28, 1999

View Archived Issues

Neurogen licenses drug discovery technology to Pfizer

Depression reduces hippocampal volume and impairs verbal memory

CyDex and Peptichemio sign licensing agreement for drug delivery technology

Olanzapine effective in management of bipolar disorder

Update on Usherdex-4 cystic fibrosis treatment candidate

BioInvent will supply Theragyn for Antisoma

Alpharma acquires Isis Pharma

Levotech's contraceptive transdermal patch in phase II/III testing

Et-743, a potent anticancer agent with a complex, unique mechanism of action

Glaxo Wellcome presents sumatriptan derivative 4991W93 at scientific meeting

LeukoSite continues to pursue a strategy of acquisition

Cambridge Antibody Technology's newest discovery poised to enter the clinic

Novel cholesterol-lowering agents in development at Takeda

Sankyo isolates novel antifungal substances from natural source

Melatonergic agents synthesized at ADIR useful for sleep disorders, anxiety, arrhythmias, etc.

Peptides with anti-Candida activity under study at Morinaga Milk

Sankyo prepares and tests new heterocyclic neuroprotective agents

HIV protease inhibitor Agenerase now available in oral solution

Thrombin-inhibitory anticoagulants prepared by Merck scientists

Pharmacia & Upjohn discloses new compounds interacting with the kynurenine metabolic pathway

WAY-133537: safe and effective agent for bladder instability

Ethyol approved by FDA for radiation-induced dry mouth

Dual AMPA receptor and voltage-gated sodium channel antagonist under study at Boehringer Ingelheim

Zeria designs dual-action arylpiperazines for BPH

Better glycemic control with insulin aspart than with human insulin

New brominated analogue of zidovudine with significantly improved lipophilicity

Nordic study of therapeutic immunization with rgp160 reported in The Lancet

Pfizer's CP-320626: mechanism of action defined

Neutrophil elastase inhibitor Ono-5046 effective in animal model of HCl-induced lung injury

Leo and SB present new p38 MAP kinase inhibitor with topical antiinflammatory activity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Hippocratic loath? ‘Harm’ threat from ACIP’s proposed HBV shift
BioWorld
Individual liberty and choice vs. wider public health became one predictable hinge upon which swung the often-acerbic debates at the CDC’s Advisory Committee for...
Høeg appointment as acting CDER director tied to vaccine strategy?
BioWorld
After a more than 13-year period of stability with Janet Woodcock as the head of CDER, with Patrizia Cavazzoni taking charge during the next four years of former...
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...